UK Markets open in 2 hrs 47 mins

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.1500+0.0300 (+0.96%)
At close: 04:00PM EDT
Full screen
Loading interactive chart…
  • Globe Newswire

    AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award

    LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Dr. Andrea Pfeifer, CEO and a Director of AC Immune, will be awarded the prestigious Aenne Burda Award for Creative Leadership at the 22nd DLD Conference to be held in Munich, Germany, May 20-22, 2022. Martin Weiss, CEO of Hubert Burda Media, commented: “Aenne Burda, was a trailblazing ro

  • Globe Newswire

    AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

    First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized formulation of the ACI-24 vaccine to enter Phase 1b/2 testing this year LAUSANNE, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publ

  • Globe Newswire

    AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine First images of alpha-synuclein in patients’ brains presented at AD/PDTM Conference provide clinical proof-of-concept for ACI-12589 as a PET tracer for alpha-synucleinopathies (e.g. MSA) Strong financial position of CHF 173.8 million ensures the Company is fully financed through